Filing Flows › Medpace Holdings (MEDP) › Oncology revenue
Medpace Holdings (MEDP) Oncology revenue by quarter
Medpace Holdings' Oncology revenue was $100M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $88.3M (Q4 2025) to $118M (Q2 2025).
| Quarter | Oncology revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $100M | +2% | -6% |
| Q2 2026 | $98.3M | +5% | -17% |
| Q1 2026 | $93.3M | +6% | -3% |
| Q4 2025 | $88.3M | -17% | — |
| Q3 2025 | $106M | -10% | — |
| Q2 2025 | $118M | +23% | — |
| Q1 2025 | $95.8M | — | — |
Q3 2026 at a glance
Medpace Holdings, Q3 2026: revenue $716M (+8% year over year), operating margin 23.1%, net earnings $137M, operating cash flow $217M. The chart follows the revenue to costs, profit and cash.
Questions
What is Medpace Holdings' Oncology revenue?
Medpace Holdings' Oncology revenue was $100M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Medpace Holdings' Oncology revenue changed?
Over the last 7 quarters it ranged from $88.3M (Q4 2025) to $118M (Q2 2025).